Acknowledgements

This research was conducted and reported under the guidance of an interagency Drug Availability Steering Committee (DASC), lead by the Drug Enforcement Administration. Members of the DASC included senior-level executives from the following organizations: Office of National Drug Control Policy, Department of Justice, Department of Defense, Department of Treasury, Drug Enforcement Administration, Crime and Narcotics Center, the U.S. Interdiction Coordinator's office, U.S. Customs Service, and U.S. Coast Guard.

The efforts of DEA's Executive Policy and Strategic Planning staff are acknowledged for initiating this effort by preparing foundational estimates of drug availability. Special recognition is deserved by the chairmen of the six Working Groups, for their diligence in completing the task in a timely fashion. These agencies include: Defense Intelligence Agency (cocaine), Crime and Narcotic Center (heroin), Drug Enforcement Administration (methamphetamine and seizures), National Drug Intelligence Center (marijuana), and Office of National Drug Control Policy (consumption).

In addition to the DASC organizations and the agencies chairing the Working Groups, the following other organizations provided data and personnel for these Working Groups and their cooperation is especially recognized: Department of State, National Guard Bureau, El Paso Intelligence Center (EPIC), National Institute of Justice, Substance Abuse and Mental Health Services Administration, Joint Interagency Task Force West, U.S. Forest Service, and Agricultural Research Service.

This effort also appreciates the support provided by the Defense Information Services Agency for providing the ADNETU WebShare forum to the Working Groups for expediting communication and information sharing.

Thanks to Ms. Bonnie Robinson, ONDCP Program Support Specialist, for providing extensive editing and publishing corrections to facilitate the final printing of this report and posting of the electronic version.

Public Domain Notice

All information appearing in this report is in the public domain and may be reproduced without permission from the authors. Citation of the source is appreciated. This report is available online at <www.WhiteHouseDrugPolicy.gov>, by selecting "Publications".